/3-Adrenergic agonists have been used extensively and successfully in the treatment of reversible airways diseases such as asthma (Djurup, 1981) . This form of therapy has proven to be particularly beneficial when the /3-stimulant drug is targeted mechanically by aerosol administration directly to the defective tissue, namely the lung. Oral administration of the /3-agonist has proven less satisfactory as cardiac and metabolic side-effects have been encountered along with peripheral muscular tremor, which have limited the usefulness of this basically effective therapy. In an attempt to extend the range of diseases amenable to treatment by 8-stimulants, the targeting of such agents to the skin was investigated. As /3-agonists are known to possess anti-inflammatory and anti-proliferative properties, a therapeutic benefit in inflammatory dermatites of an acute or chronic nature, and in inflammatory proliferative diseases such as psoriasis, could be anticipated.
It has been recognized for many years that cyclic AMP is the 'second messenger' involved in the transmission of the primary signal due to /3-adrenoceptor stimulation and that cyclic AMP is intimately involved in the modulation of inflammatory reactions (Bourne et al., 1974) . Thus in the model in vitro of the immediate hypersensitivity reaction in the human basophil, histamine secretion is triggered by the combination of antigens with specific immunoglobulin E antibody bound to the cell membrane. /3-Adrenergic catecholamines, arachidonic acid metabolites and histamine itself, agents which stimulate the accumulation of intracellular cyclic AMP by activating adenylate cyclase, prevent antigen-induced histamine release. The human polymorphonuclear neutrophil when triggered by contact with immune complexes releases lysosomal hydrolases. This enzyme release is inhibited by agents which raise intracellular cyclic AMP levels, namely prostaglandins and /3-adrenergic agonists. A cellmediated immune response, as elicited by T-lymphocytes derived from the spleens of mice immunized with allogeneic cells, which has been shown to effect cytolysis of cells bearing the appropriate alloantigen, can be inhibted by agents which raise intracellular cyclic AMP levels. Blymphocytes, as a result of antigenic stimulation, differentiate into antibody-secreting plasma cells. /3-Adrenergic catecholamines, histamine and arachidonic acid metabolites as well as methylxanthines, dibutyryl cyclic AMP and cholera endotoxin, inhibit either the production or secretion of antibody in this humoral immune response reaction. A number of recent clinical dermatological observations supporting this general thesis include: the successful treatment of atopic dermatitis with caffeine, a phosphodiesterase inhibitor (Kaplan et al., 1976 (Kaplan et al., , 1978 , the use of isoprenaline in psoriasis (Das et al., 1978) , and the use of various agents which modulate cyclic AMP in the treatment of urticaria (Keahey & Greaves, 1980) . Cyclic AMP is predominantly located in the cytoplasm of the germinative or basal cells of the epidermis. In the skin, as in other tissues, the formation of cyclic AMP from ATP is catalysed by a membrane-bound adenylate cyclase, and cyclic AMP is hydrolysed to 5'AMP by cyclic nucleotide phosphodiesterase, which may be present in multiple forms in the skin. Cyclic AMP-dependent protein kinase is thought to mediate all the effects of cyclic AMP in the epidermis and has been demonstrated to exist in different forms in monkey, adult and neonatal skin. Normal human epidermis contains approx. 0.24.4 pmol of cyclic AMP/ pg of DNA. Values for psoriatic involved and uninvolved tissues have been determined mainly by Voorhees et al., (1973) , but also by Harkonen et al. (1974) and Yoshikawa et al. (1975) , and suggest that there is an abnormality in the cyclic AMP system in psoriasis, with a decrease in the lesional tissue levels of cyclic AMP associated with the disease process. Treatment of the psoriatic lesions with the topical use of the phosphodiesterase inhibitor papaverine and also with L-dihydroxyphenylalanine and fenfluramine, agents which raise intracellular cyclic AMP levels, supports the general hypothesis. Cyclic GMP is also present in the dermis in much smaller amounts, ranging from 5 to 7 fmol/pg of DNA, and shows a statistically highly significant two-fold increase in the lesional epidermis.
Against this background the search for a topically active /3-adrenergic agonist for use in skin diseases was undertaken. The prodrug approach was considered, as the prototype agonist isoprenaline showed poor bioavailability, potency and duration of action when applied topically. The required agent should produce no untoward cardiovascular side-effects when applied topically and have significantly improved chemical stability, as compared with isoprenaline, in a cream or gel formulation.
The /3-adrenergic agents synthesized were evaluated in the mouse-ear croton-oil-induced inflammation model (Glenn et al., 1978; Green et al., 1984 , and references therein) as a primary screen. This screen was deemed suitable as the rank order of potency for the corticosteriods is identical to that found for these agents in the more definitive vasoconstriction-forearm blanching screens for topical anti-inflammatory agents. Isoprenaline was inactive in this screen; moderate activity was observed for salbutamol and high activity for clenbuterol (Table 1) . Non-steriodal anti-inflammatory agents were inactive at reasonable dose levels. As a result of such testing and further chronic administration studies, two compounds, ICI 125,436 (111) and 116,258 (VII), were selected for further anti-inflammatory evaluation.
The duration of the anti-inflammatory effect for these compounds was determined by preadministration of drug followed, after various time intervals, by the croton oil. In this way predosing by up to 4 h had no significant effect on the anti-inflammatory potency of salbutamol, ICI 116,258 and 125,436. In cross-ear experiments, where the drug was administered to one ear and the croton oil to the other ear, a systemic IC,, was determined. Salbutamol was found to penetrate the skin fairly rapidly with an IC,, of 297pg/ear after application to the contralateral ear, this dose being only three times that required to produce an IC,, in the standard crotonoil screen. Both ICI 125,436 and 116,258 showed higher ratios of systemic to topical anti-inflammatory doses and were therefore considered to be safer. Further evaluation of these compounds in the mouse contact sensitivity to 4-ethoxy-methylene-2-phenyl-oxazolone (oxazolone) screen (Evans et al., 1971) confirmed their anti-inflammatory activity, even though their potency in this screen, as compared with the croton-oil-induced inflammation screen, was lower. The ability of this class of compound to affect another important facet of the inflammatory process was exemplified by their activity in inhibiting the release of /3-glucuronidase, a lysosomal 1986 enzyme, into blood after the intravenous injection of carbon particles to activate the reticuloendothelial system. ICI 1 10,641, a close analogue of ICI 125,436, showed a highly significant inhibition (47-60%) of this response at a dose of I00 pg/kg. Since clinical psoriasis has a definite proliferative component, the activity of ICI 116,258 as an inhibitor of DNA synthesis in the essential-fatty-acid-deficient-mouse model (Lowe ef af., 1981) was particularly relevant. The anti-proliferative activity in this model was vehicledependent, and was maximal for a formulation containing 3.5% azone added as a penetration enhancer. As both the anti-inflammatory and cell division processes can be modulated by changes in cyclic AMP concentration, a direct measure of the capacity of the anti-inflammatory /?-agonists to alter this parameter was considered essential. C6-glioma cells were stimulated using the test /?-agonist and the percentage conversion of tritiated ATP to cyclic AMP measured; good activity was observed for isoprenaline and ICI 125,436 whilst salbutamol and ICI 116,258 were inactive (Table I) .
The synthesis of ICI 116,258 and 125,436 proceeded by conventional routes from catechol (Scheme I). The key step in the preferred route for the preparation of ICI 125,436 (111) involved a reductive amination of 3,4-dipivaloyloxyphenylglyoxal (I) with N-(2-amino-2-methylpropyl)-2-phenoxy acetamide (11) using sodium cyanoborohydride at pH 4 as the reducing agent. ICI 1 16,258 was prepared using the bromo-ketone route in which 3'4'-dipivaloyloxy-2-bromoacetophenone (IV) was condensed with N-(2-benzylamino ethyl)-2-(4-chlorobenzamide) (V) and the resulting amino ketone reduced to the ethanolamine with sodium borohydride and debenzylated by catalytic hydrogenation to give the desired hydrobromide salt of ICI 116,258 (VII).
A series of aliphatic acid diesters of the catechol /?-stimulant ethanolamines was prepared by hydrolysis of 3'4'-diacetoxy-2-[N-benzyl-2-(2-phenylacetamido)ethylaminolacetophenone (VIII), followed by re-esterification reduction of the ketonic function, and debenzylation to the desired ethanolamines (IX). Arrangement of this series of diesters in order of increasing steric hinderance (Sniegoski, 1976) (sum of the '2's' and '3's' in the carboncarbon bond pattern number) reveals a good correlation, for the less hindered members, between the relative esterification rates of the esters and their topical antiinflammatory potency. The topical anti-inflammatory potency peaks at the level of dipivaloyloxy esters and further increases in steric hindrance seem dystherapeutic.
It is important that before a /?-stimulant can be regarded as a topical anti-inflammatory agent that its safety is assured. Drug applied to the skin must not reach the systemic circulation in sufficient concentration to cause heart rate or blood pressure changes. The cardiovascular effects of each /?-stimulant molecule synthesized was therefore determined in the conscious rat after intravenous and topical dosing to normal and adhesive-tapestripped skin. The rats were cannulated under fluothane anaesthesia, allowed 2 days to recover, then treated with syrosingopine to deplete endogenous catecholamines, and the test compound applied either intravenously or topically. From the appropriate dose-response curves, heart rate and blood pressure ED,, values were determined by both the intravenous and topical routes ( Table 2 ). The ratio of the heart rate ED,, to the blood pressure ED,, gives a measure of the selectivity of the test compound, whilst the therapeutic index (the ratio of the topical stripped heart rate ED,, to the topical antiinflammatory ID,,) related the safety of the compound to its efficacy. Thus, salbutamol shows /?,-selectivity whilst ICI 125,436 and 116,258 are non-selective; however, both ICI 125,436 and 116,258 show greatly superior therapeutic indices to that observed for salbutamol. The biological half-lives for elimination of ICI 125,436 and 116,258 were measured in both the rat and dog, and were respectively 50 and 57min, and 26 and 26min, Vol. 14 considerably shorter than that observed for salbutamol (Table 3) . These shorter half-lives of elimination could prove to be significant clinical safety features.
The absorption, pharmacokinetics and metabolism of ICI 125,436 and 116,258 were studied in the rat and dog, by both oral and topical routes using 3H-and ''C-labelled compounds. The bioavailability of both compounds when dosed orally at 100 pg/kg was in, excess of go%, peak plasma levels being reached after 1 4 h, with peak concentrations in the range 40-120 ng equivalents/ml. The main route of excretion in rat was biliary (66%), whereas in the dog excretion was evenly balanced between biliary (50%) and urine (50%). After a single topical dose, no more than 5% of the applied dose was recovered in the excretion; daily urinary and faecal recovery values were constant, implying a sustained low level of daily absorption. The main metabolites identified and characterized by isolation and comparison with authentic samples, after oral administration of ICI 116,258, were N-[2-(4-chloro-benzamido)ethyl]-N-2-hydroxy-2-[4-hydroxy-3-methoxyphenyl]ethylammonium bromide and 4-chlorobenzoic acid. These were present both as free compounds and as glucuronides. The former was clearly the product of esterase hydrolysis followed by reaction with catechol 0-methyltransferase, confirming that the metabolic deactivation pattern was identical to that observed for the natural catecholamines. The stability of ICI 1 16,258 was examined in considerable detail, both in aqueous or buffered aqueous media and in organic solvents. The main degradative route in aqueous formulations concerned ester hydrolysis, which was minimal at increasing in both the acid and the alkaline direction. Satisfactory shelf-lives, with less than 10% decomposition in 2 years at 23"C, were easily achieved by such aqueous formulations. In organic solvents an oxidative, probably peroxide-mediated, decomposition pathway was also encountered. Satisfactory storage characteristics were observed in the untreated alcohols ethanol, isopropanol and t-butanol; however, in order to realize satisfactory stability in benzyl alcohol and carbitol it was necessary to free these solvents from peroxide contaminants. Thus, the prodrug showed more than adequate stability profiles in marked contrast to those observed for the parent drug.
The penetration of H3-labelled ICI 125,436 through stratum corneum in vitro was determined directly using a skin cell (Scheuplein & Ross, 1974) . The rate of penetration was formulation dependent with a basal rate of 0.68 ng/cm2 per h from a methanol deposited film being observed. The penetration was also characterized by a lag phase of up to 109 h. Percutaneous absorption rates for ICI 116,258 increased by up to 20-fold were observed in the presence of the penetration enhancer I-dodecylhexahydro-2H-azepin-2-one (azone) at 5% concentration. In a comparative experiment between ICI 116,258 and ['4C]fluocinolone acetonide, ('Synalar') ICI 1 16,258 showed a superior percutaneous absorption rate which was 3.5 times that of the steriod.
As all the biological data so far reported have been accumulated in rodents, it was of considerable interest to investigate the anti-inflammatory properties of the p-stimulants in species, whose skin was more akin to human skin; to this end the domestic pig was selected (Bilski & Thomson, 1984) . Five female domestic pigs were used for each experiment; six pairs of sites were identified on either sides of the backbone of each pig. The drug or control vehicle was applied in a properly randomized fashion to the test sites; 24 h later, increasing doses (l%, 5% and 10% in acetone) of oxazolone were applied to both the standard and experimental sites. This was immediately followed by reapplication of the formulation or vehicles to their respective sites. Thirty hours later, the lesions were assessed for erythema, area and transepidermal water loss.
Using the Wilcoxon Rank Test for statistical analysis of the results, the various treatment regimes were compared. Thus, on the severe and very severe lesions treatment with 'Synalar' or with a 1% formulation of ICI 1 16,258 containing 3.5% of azone were indistinguishable.
The cardiovascular safety of the /?-stimulant drugs was also investigated in pigs, a topical dose of the drug in an appropriate occluded formulation was administered, and any cardiovascular response monitored by remote telemetry. ICI 116,258, when applied topically to porcine skin under conditions promoting maximal penetration of the drug, failed to elicit an increase in heart rate.
